Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
REVIEW

Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia

Dorota M. Gertig A , Julia M. L. Brotherton A B and Marion Saville A

A Victorian Cytology Service, PO Box 161, Carlton South, Vic. 3053, Australia.

B Corresponding author. Email: jbrother@vcs.org.au

Sexual Health 8(2) 171-178 http://dx.doi.org/10.1071/SH10001
Submitted: 4 January 2010  Accepted: 21 May 2010   Published: 18 May 2011

Abstract

Accurate estimates of HPV vaccination coverage are critical for determining the proportion of the target female population that is not protected by the vaccine, as well as for monitoring the performance of vaccine delivery programs. The implementation of an HPV vaccination register, either as part of an existing immunisation register or stand-alone, can add substantial benefits to an HPV vaccination program. In Australia, the National HPV Vaccination Program Register supports the HPV vaccination program by providing information to consumers and providers about incomplete courses as well as estimates of vaccination coverage by age and area. Future monitoring of vaccine effectiveness will be facilitated by cross-linking to Pap test registries.

Additional keywords: genital warts, monitoring, papillomavirus.


References

[1]  Brotherton JM 2008 How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 26 250 6 doi:10.1016/j.vaccine.2007.10.057

[2]  International Agency for Research on Cancer/World Health Organization. IARC Handbooks of cancer prevention: cervix cancer screening. Lyon: IARC/WHO; 2005.

[3]  Garland SM Steben M Sings HL James M Lu S Railkar R et al 2009. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis doi:10.1086/597071

[4]  Ault KA 2007 Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 1861 8 doi:10.1016/S0140-6736(07)60852-6

[5]  Paavonen J Jenkins D Bosch FX Naud P Salmeron J Wheeler CM et al 2007 Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 2161 70 doi:10.1016/S0140-6736(07)60946-5

[6]  Paavonen J Naud P Salmeron J Wheeler CM Chow SN Apter D et al 2009 Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 301 14 doi:10.1016/S0140-6736(09)61248-4

[7]  Wheeler CM Kjaer SK Sigurdsson K Iversen OE Hernandez-Avila M Perez G et al 2009 The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis doi:10.1086/597309

[8]  Bonanni P Boccalini S Bechini A 2009 Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 27 Suppl 1 A46 53 doi:10.1016/j.vaccine.2008.10.085

[9]  ECCA (European Cervical Cancer Association). HPV vaccination across Europe, 2009. Available online at: http://www.ecca.info [verified June 2010].

[10]  Koulova A Tsui J Irwin K Van Damme P Biellik R Aguado MT 2008 A brief report: country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006–January 2008. Vaccine 26 6529 41 doi:10.1016/j.vaccine.2008.08.067

[11]  King LA Levy-Bruhl D O’Flanagan D Bacci S Lopalco PL Kudjawu Y et al 2008 Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: Results of the VENICE 2007 survey. Euro Surveill 7–9 13

[12]  Australian. Government, Department of Health. National immunisation program. Available online at:
http://www.immunise.health.gov.au/ [verified June 2010].

[13]  Fairbrother G Freed GL Thompson JW 2000 Measuring immunization coverage. Am J Prev Med 19 78 88 doi:10.1016/S0749-3797(00)00208-7

[14]  Cuzick J Castanon A Sasieni P 2010 Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK. Br J Cancer 102 933 9 doi:10.1038/sj.bjc.6605528

[15]  Franco EL Cuzick J 2008 Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 26 A16 23 doi:10.1016/j.vaccine.2007.11.069

[16]  Franco EL Cuzick J Hildesheim A de Sanjose S 2006 Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 S171 7

[17]  Tota J Mahmud SM Ferenczy A Coutlée F Franco EL 2010 Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. Sex Health 7 376 82
doi:10.1071/SH10022

[18]  Dobson S , Dawar M , Scheifele D , Kollman T , McNeil S , Halperins S et al Are 2 doses of HPV vaccine adequate in girls? [conference abstract O-29.4]. 25th International Papillomavirus Conference Clinical & Educational Workshop, May 8–14 Malmo, Sweden; 2009.

[19]  NHMRC. The Australian immunisation handbook 9th edition, 2008. Canberra: Australian Government; 2008.

[20]  Department of Health and Ageing. Guidance on revaccination where HPV vaccine doses have been given at less than recommended minimum intervals. Canberra: Australian Government. Department of Health and Ageing; 2009. Available online at: http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/cmo-full-advice-hpv-cnt/$File/CMO-full-advice-hpv.pdf [verified June 2010].

[21]  Ault KA 2007 Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 107 S27 30 doi:10.1016/j.ygyno.2007.07.078

[22]  The National Health Amendment Act 2007. Canberra: Australian Government; 2007. Available online at: http://fedlaw.gov.au/ComLaw/Legislation/Act1.nsf/0/08C0837265607CA9CA2573FB00098717/$file/1352007.pdf [verified June 2010].

[23]  Public summary document for quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, injection, 0.5 mL, Gardasil®. Canberra: Australian Government, Department of Health and Ageing. Available online at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-gardasil-nov06 [verified November 2009].

[24]  Hull BP Deeks SL McIntyre PB 2009 The Australian Childhood Immunisation Register – a model for universal immunisation registers? Vaccine 27 5054 60 doi:10.1016/j.vaccine.2009.06.056

[25]  Young M , Morrell S , Harris W . Recruitment of women from a culturally and linguistically diverse background: Arabic, Cantonese, Mandarin, Korean and Spanish speaking women. NSW: NSW Cervical Screening Program & NSW Multicultural Health Communication Service; 2001.

[26]  Taylor RJ Mamoon HA Morrell SL Wain GV 2001 Cervical screening in migrants to Australia. Aust N Z J Public Health 25 55 61 doi:10.1111/j.1467-842X.2001.tb00551.x

[27]  Weber MF Banks E Smith DP O’Connell D Sitas F 2009 Cancer screening among migrants in an Australian cohort; cross-sectional analyses from the 45 and Up study. BMC Public Health 9 144 doi:10.1186/1471-2458-9-144

[28]  HPV Vaccination Coverage. Statens Serum Institut-News-EPI NEWS No 6, 10/2/2010. Available online at: http://www.ssi.dk/English/News/EPI-NEWS/2010 [verified April 2011].

[29]  HPV Vaccination Programme: Provisional data, as submitted by PCTs for First, Second and Third dose vaccine uptake, for the month ending 31 August, 2009. London: National Health Service. Available online at: http://www.immunisation.nhs.uk/publications/HPV_VaccineUptake_Aug2009.pdf [verified June 2010].

[30]  Human Papillomavirus (HPV) Vaccine Uptake Annual Survey 2008/09. PCT Immunisation Coordinator User Guide for Determining the Annual Denominator and Vaccine Uptake of the ImFrom Website. Available online at: http://www.immunisation.nhs.uk/publications/HPV_AnnualReturnGuidance_acc.pdf [verified June 2010].

[31]  NHS National Service. Child health. Childhood immunisations. Edinburgh: NHS National Service; 2010. Available online at: http://www.isdscotland.org/isd/5921.html [verified June 2010].

[32]  Public Health Wales. Vaccine uptake in children in Wales October to December 2009. Public Health Cover Report. Public Health Wales, Vaccine Preventable Disease Programme and Communicable Disease Surveillance Centre. Available online at: http://www.wales.nhs.uk/sites3/Documents/457/Cov09q4%20%5Freport93.pdf [verified June 2010].

[33]  Ministry of Health of Quebec. FlashVigie Bulletin Quebecois de vigie et d’entervention en maladie infectieuses, Vol. 4, No. 1, January 2009. Quebec: Ministry of Health; 2009.

[34]  Colucci R Hryniuk W Savage C 2008 Prevention: HPV Vaccination Programs in Canada. Report card on cancer in Canada, Winter 2008–2009. Cancer Advocacy Coalition of Canada 11 7 8

[35]  British Columbia Centre for Disease Control. Grades 6 and 9 female students who received the first dose of HPV vaccine, British Columbia. Available online at:
http://www.bccdc.ca/NR/rdonlyres/0BE35108-CCBD-4DED-8EB8-62EA80213A21/0/EPI_Report_HPVPublicGrade6and9_Mar10_20100322.pdf [verified June 2010].

[36]  Centers for Disease Control and Prevention 2009 National, state, and local area vaccination coverage among adolescents aged 13–17 years – United States, 2008. Morb Mortal Wkly Rep 58 997 1001



Export Citation